Vanguard Capital Management
AARD

Vanguard Capital Management’s Aardvark Therapeutics AARD Stock Holding History

Vanguard Capital Management’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.24M Buy
562,877
+8,776
+2% +$41K ﹤0.01% 3263
2026
Q1 		$2.09M Buy
+554,101
New +$5.74M ﹤0.01% 3350

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.23B AUM 74.49% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management's AARD Position: Q2 2026 in Review

Vanguard Capital Management increased its Aardvark Therapeutics (AARD) stake by 1.6% in Q2 2026, buying an estimated $41K and bringing the position to 562,877 shares worth $3.24M. The position accounts for ﹤0.01% of the portfolio, ranked #3263.

Vanguard Capital Management first reported a position in AARD in Q1 2026 and has held it in 2 quarters since. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Vanguard Capital Management held 562,877 shares of Aardvark Therapeutics worth $3.24M as of Q2 2026.
  • Vanguard Capital Management bought 8,776 Aardvark Therapeutics shares in Q2 2026, an estimated $41K.
  • Aardvark Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3263 holding.
  • Vanguard Capital Management first reported a position in Aardvark Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.